These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18574133)

  • 1. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients.
    Sluimer JD; van der Flier WM; Karas GB; Fox NC; Scheltens P; Barkhof F; Vrenken H
    Radiology; 2008 Aug; 248(2):590-8. PubMed ID: 18574133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures.
    Henneman WJ; Sluimer JD; Barnes J; van der Flier WM; Sluimer IC; Fox NC; Scheltens P; Vrenken H; Barkhof F
    Neurology; 2009 Mar; 72(11):999-1007. PubMed ID: 19289740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia.
    Smith EE; Egorova S; Blacker D; Killiany RJ; Muzikansky A; Dickerson BC; Tanzi RE; Albert MS; Greenberg SM; Guttmann CR
    Arch Neurol; 2008 Jan; 65(1):94-100. PubMed ID: 18195145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors.
    Sluimer JD; Vrenken H; Blankenstein MA; Fox NC; Scheltens P; Barkhof F; van der Flier WM
    Neurology; 2008 May; 70(19 Pt 2):1836-41. PubMed ID: 18458218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
    Sluimer JD; Bouwman FH; Vrenken H; Blankenstein MA; Barkhof F; van der Flier WM; Scheltens P
    Neurobiol Aging; 2010 May; 31(5):758-64. PubMed ID: 18692273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline.
    den Heijer T; van der Lijn F; Koudstaal PJ; Hofman A; van der Lugt A; Krestin GP; Niessen WJ; Breteler MM
    Brain; 2010 Apr; 133(Pt 4):1163-72. PubMed ID: 20375138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.
    Devanand DP; Pradhaban G; Liu X; Khandji A; De Santi S; Segal S; Rusinek H; Pelton GH; Honig LS; Mayeux R; Stern Y; Tabert MH; de Leon MJ
    Neurology; 2007 Mar; 68(11):828-36. PubMed ID: 17353470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations.
    Evans MC; Barnes J; Nielsen C; Kim LG; Clegg SL; Blair M; Leung KK; Douiri A; Boyes RG; Ourselin S; Fox NC;
    Eur Radiol; 2010 Mar; 20(3):674-82. PubMed ID: 19760240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression.
    Ridha BH; Anderson VM; Barnes J; Boyes RG; Price SL; Rossor MN; Whitwell JL; Jenkins L; Black RS; Grundman M; Fox NC
    J Neurol; 2008 Apr; 255(4):567-74. PubMed ID: 18274807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment.
    McEvoy LK; Fennema-Notestine C; Roddey JC; Hagler DJ; Holland D; Karow DS; Pung CJ; Brewer JB; Dale AM;
    Radiology; 2009 Apr; 251(1):195-205. PubMed ID: 19201945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
    Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Chan M; Ghassemi A
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):106-112. PubMed ID: 26420886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
    DeCarli C; Frisoni GB; Clark CM; Harvey D; Grundman M; Petersen RC; Thal LJ; Jin S; Jack CR; Scheltens P;
    Arch Neurol; 2007 Jan; 64(1):108-15. PubMed ID: 17210817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.
    Jack CR; Petersen RC; Xu Y; O'Brien PC; Smith GE; Ivnik RJ; Boeve BF; Tangalos EG; Kokmen E
    Neurology; 2000 Aug; 55(4):484-89. PubMed ID: 10953178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.
    Jack CR; Shiung MM; Gunter JL; O'Brien PC; Weigand SD; Knopman DS; Boeve BF; Ivnik RJ; Smith GE; Cha RH; Tangalos EG; Petersen RC
    Neurology; 2004 Feb; 62(4):591-600. PubMed ID: 14981176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Brain Magnetic Resonance Imaging Signs With Cognitive Outcomes in Persons With Nonimpaired Cognition and Mild Cognitive Impairment.
    Wu A; Sharrett AR; Gottesman RF; Power MC; Mosley TH; Jack CR; Knopman DS; Windham BG; Gross AL; Coresh J
    JAMA Netw Open; 2019 May; 2(5):e193359. PubMed ID: 31074810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus.
    Colliot O; Chételat G; Chupin M; Desgranges B; Magnin B; Benali H; Dubois B; Garnero L; Eustache F; Lehéricy S
    Radiology; 2008 Jul; 248(1):194-201. PubMed ID: 18458242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease.
    Spampinato MV; Rumboldt Z; Hosker RJ; Mintzer JE;
    Radiology; 2011 Mar; 258(3):843-52. PubMed ID: 21163916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity.
    Binnewijzend MA; Kuijer JP; Benedictus MR; van der Flier WM; Wink AM; Wattjes MP; van Berckel BN; Scheltens P; Barkhof F
    Radiology; 2013 Apr; 267(1):221-30. PubMed ID: 23238159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD.
    Vemuri P; Weigand SD; Knopman DS; Kantarci K; Boeve BF; Petersen RC; Jack CR
    Neuroimage; 2011 Jan; 54(2):985-91. PubMed ID: 20832487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.